nf-κb-inducing kinase nik

B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins.

NIK SMI1 is an effective and selective NF-κB inducing kinase (NIK) inhibitor. It also inhibits NIK-catalyzed hydrolysis of ATP to ADP (IC50: 0.23±0.17 nM).

NIK-IN-2 (compound 1) is an effective inhibitor of NF-κB inducing kinase (NIK), exhibiting a pIC50 of 7.4. It plays a crucial role in cancer research.

XT2 is a highly potent, orally active, and selective inhibitor of NF-κB-inducing kinase (NIK), exhibiting an IC50 of 9.1 nM. It effectively suppresses the upregulation of ALT, a vital biomarker for acute liver injury, induced by CCl4. Additionally, XT2 significantly decreases immune cell infiltration into the damaged liver tissue. As a result, XT2 holds immense potential in liver inflammatory disease research [1].

AM0216 is a novel highly potent inhibitor of NF-κB inducing Kinase (NIK).

IR-Crizotinib is a conjugate of the near-infrared dye IR-786 and Crizotinib, an NF-κB-inducing kinase (NIK) inhibitor, with an IC50 of 3.381 μM for intracranial glioblastoma (GBM) localization in mice. It has the ability to cross the blood-brain barrier and fluorescently mark GBM, and demonstrates efficacy in inhibiting glioma proliferation and invasion both in vitro and in vivo, making it significant in cancer research [1].